On Wednesday, Halozyme Therapeutics, Inc. (HALO) stock saw a decline, ending the day at $53.46 which represents a decrease of $-0.36 or -0.67% from the prior close of $53.82. The stock opened at ...
Bloomberg Editor-in-Chief Emeritus, Matthew Winkler, sees Taiwan as a bastion of prosperity, with its stock market outperforming the world, and price stability making its debt the least risky in the ...
When an eligible appraisal passes Reggora's automated review, Reggora now covers any financial loss associated with a repurchase / LLPA adjustment due to an appraisal defect ...
Because it helps me follow the money! Long-time readers know how important the distinction between primary and secondary shares can be for something like an IPO or a strategic investment, but for new ...